HIV-1-infection
Conditions
Keywords
HIV
Brief summary
The study is conducted in two stages and open-label stage of the study. At the first stage of the study, the main purpose was to choose the optimal dose of VM-1500 (20 mg or 40 mg per day) in addition to standard-of-care basic antiretroviral therapy consisting of two NRTIs, in terms of reduction of viral load at Week 12 (\<400 copies/ml) in treatment-naïve HIV-1-infected patients. At the second stage of the study, the main purpose was to evaluate efficacy of VM- 1500 (in the optimal dose selected at the first stage of the study) in comparison to Efavirenz added to standard-of-care antiretroviral therapy of two NRTIs, in terms of reduction of viral load at Week 24 to the undetectable level (\<50 copies/ml) in treatment-naïve HIV-1 infected patients. Open-label stage of the study continued evaluation of viral load and immunological and safety parameters in HIV-1 patients receiving VM-1500 up to Week 96 and additional PK up to Week 100.
Detailed description
This project is an international, multicenter, randomized, partially blind clinical study to evaluate efficacy and safety of two different doses of VM-1500 in comparison with Efavirenz added to standard antiretroviral therapy including two NRTIs in treatment-naïve HIV-1-infected patients.
Interventions
DRUGVM-1500
VM-1500 up to 96 weeks
DRUGEfavirenz
Efavirenz up to 48 weeks
Antiretroviral therapy up to 96 weeks
Sponsors
Viriom
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed Patient Information and Informed Consent Form. 2. Males and females, age ≥ 18 years. 3. HIV-1 infection, confirmed serologically in IFA or immunoblot analysis (or documented HIV-1 infection). 4. Clinically stable HIV infection (clinical stages 1 or 2 according to the WHO classification). 5. Indications (in the Investigator's opinion) for ART, according to the WHO Summary Guideline for use of antiretroviral drugs in HIV prevention and treatment (2013). 6. HIV-1 RNA plasma level ≥ 5 000 copies/ml at screening. 7. СD4+ Т-cells number \> 200 cells/mm3 at screening. 8. Laboratory parameters as follows: White blood cells ≥ 2900/mm3 (2,9 x 109 cells/l) Absolute neutrophils ≥ 1500/mm3 (1,5 x 109 cells/l) Platelets ≥ 100000/mm3 (100 x 109 cells/l) Hemoglobin ≥ 9.0 g/dl Total bilirubin ≤ 1.5 x ULN AST and ALT≤ 2.5 x ULN Renal function GFR \> 60 ml/min
Exclusion criteria
1. Primary HIV-1 resistance to ART. Viral resistance mutations are defined as any basic mutations of resistance to NNRTIs, according to the updated list of VIH-1 resistance mutations (International AIDS society, 2013), associated with drug resistance in any genotype. 2. History of antiretroviral therapy (ART), including for the prevention of vertical transmission of HIV. 3. Acute hepatitis or hepatic cirrhosis of any etiology; anti-HCV antibodies or HBsAg at screening. 4. Signs of acute infection or positive test result for syphilis, hepatitis A, Toxoplasma gondii, cytomegalovirus, gonorrhea, Chlamydia trachomatis during 30 days before screening. 5. Opportunistic infections of the Category C (Centers of Disease Control (CDC), 2008), excluding Kaposi's sarcoma not requiring systemic therapy. 6. History of tuberculosis of any localization, or tuberculosis at screening, according to x-ray examination. 7. History of malignant tumors (except basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ, eliminated and cured ≥ 5 years ago).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction of HIV-1 RNA level in blood plasma <400 copies/ml | 12 weeks | Comparison of the percentage of patients with reduced viral load to \< 400 copies/ml at Week 12 in VM-1500 20 mg, VM-1500 40 mg and Efavirenz treatment groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reduction of HIV-1 RNA level in blood plasma <50 copies/ml | 24 weeks | Comparison of the percentage of patients with reduced viral load to an undetectable level (\< 50 copies/ml) at Week 24 in VM-1500 group with the selected dose and Efavirenz group. |
| Change in the absolute CD4+ lymphocytes count | 48 weeks | Change in the absolute CD4+ lymphocytes count from Baseline to Week 48 in VM-1500 group with the selected dose and Efavirenz group. |
| Change in the absolute CD8+ lymphocytes count | 48 weeks | Change in the absolute CD8+ lymphocytes count from Baseline to Week 48 in VM-1500 group with the selected dose and Efavirenz group. |
| The percent of patients with study therapy-resistant HIV-1 development | 48 weeks | The proportion of patients who develop study therapy-resistant HIV-1 from Baseline to Week 48 in VM-1500 group with the selected dose and Efavirenz group. |
Countries
Russia
Outcome results
None listed